ESCMID Young Investigator Awards for Research in CM and ID

Michele Bartoletti
Bologna, Italy
Epidemiology and clinical management of infections in patients with liver cirrhosis

Michele Bartoletti is an Infectious Disease Physician of IRCCS Sant’Orsola and Assistant Professor of Infectious Disease of University of Bologna. He has been graduated in Medicine and Surgery in 2008, has completed his infectious disease training in 2014 and received Ph.D. in 2018. As Infectious Disease Physician he is involved in care of critically ill and immunocompromised patients including patients with hematological disease and transplant recipients. His main research interests have been infections in the immunocompromised host, critically ill patients, and patients with liver cirrhosis. During the COVID-19 pandemic he has been involved in a series of studies related to epidemiological aspects of COVID-19 including bacterial and fungal superinfections complicating severe COVID-19. He was the chair of ESCMID COVID-19 treatment guidelines. In 2021 he received recognition as top reviewer for Clinical Microbiology and Infection.

Timothy Rawson
London, United Kingdom
Can artificial intelligence and real-time monitoring support optimised antimicrobial use?

Tim is an NIHR Academic Clinical Fellow in Infectious Diseases and Medical Microbiology and Honorary Clinical Lecturer at Imperial College London. He completed his PhD in 2018 exploring personalised antimicrobial management in secondary care. In 2017 he was awarded the British Infection Association (BIA) Barnett Christie Award for Excellence in Original Research. Tim currently works within the Centre for Antimicrobial Optimisation (CAMO) at Imperial College London and is the Research Theme Lead for Precision Prescribing in the NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance (HPRU in HCAI and AMR).

Tim’s research interests focus on antimicrobial stewardship and in precision prescribing of antimicrobials. This includes the development and implementation of artificial intelligence-based clinical decision support systems, biosensor-based methods for intermittent and continuous drug monitoring, and therapeutically beneficial drug-drug interactions. During the pandemic he has been involved in investigating the impact of COVID-19 on bacterial infections and antimicrobial use and supported the development of appropriate frameworks for monitoring and surveillance.